Form 4: Casdin Funds Increase Standard BioTools Stake

Casdin Partners Master Fund and affiliated entities significantly increased their beneficial ownership in Standard BioTools Inc. through open market purchases in November 2025.

Summary

• Casdin Partners Master Fund, L.P. and related entities acquired a total of 1,175,000 shares of Standard BioTools Inc. common stock between November 7 and November 12, 2025.
• The acquisitions were made at weighted average prices ranging from $1.1153 to $1.2053 per share.
• Following these transactions, the Casdin group's indirect beneficial ownership through Casdin Partners Master Fund, L.P. increased to 62,050,000 shares.
• Eli Casdin, who is a managing member of several Casdin entities, directly owns 2,901,062 shares.
• Additional indirect beneficial ownership includes 13,939,637 shares through Casdin Private Growth Equity Fund II, L.P. and 2,744,219 shares through Casdin Private Growth Equity Fund, L.P.
• The reporting persons, including Eli Casdin, are identified as both Directors (by deputization) and 10% Owners of Standard BioTools Inc.

Sentiment

Score: 8

Explanation: The significant open market purchases by a major institutional investor and director indicate strong confidence in the company's valuation and future prospects, which is a highly positive signal for the stock.

Positives

• Significant insider buying by a major shareholder and director, indicating strong confidence in the company's future prospects.
• The purchases were made in the open market, suggesting a belief that the current stock price represents a good value.
• Increased alignment of interests between a major institutional investor/director and other shareholders.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• Eli Casdin has been deputized to represent the Reporting Persons on the board of directors of the Issuer.
• By virtue of Mr. Casdin's representation, for purposes of Section 16 of the Securities Exchange Act of 1934 (the "Exchange Act"), each of the Reporting Persons may be deemed directors by deputization of the Issuer.
• Each Reporting Person disclaims beneficial ownership in the securities reported on this Form 4 except to the extent of its pecuniary interest, if any, therein, and this report shall not be deemed to be an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.

Industry Context

The increased stake by a prominent life sciences investor group like Casdin Partners could signal a positive long-term view on Standard BioTools' position within the biotechnology and life sciences tools sector, potentially anticipating future growth or strategic developments.

Corporate Governance

Stakeholder Impact

• Shareholders: Likely to view the insider buying as a positive sign of confidence from a significant investor, potentially boosting investor sentiment and share price.
• Management: Reinforces alignment with a major shareholder and board member, potentially influencing strategic decisions.

Key Dates

Recommendation

The substantial open market purchases by Casdin Partners and affiliated entities, who are both 10% owners and have a deputized director on the board, represent a strong vote of confidence. Insider buying, especially by a sophisticated institutional investor with board representation, often signals that the insiders believe the stock is undervalued or that significant positive developments are anticipated. This increased alignment of interests suggests a favorable outlook for Standard BioTools Inc.

Keywords

STANDARD BIOTOOLS, LAB, Casdin Partners, Eli Casdin, Insider Buying, Form 4, Equity Acquisition, 10% Owner, Director, Biotechnology, Life Sciences